Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
出版年份 2017 全文链接
标题
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
作者
关键词
-
出版物
LEUKEMIA
Volume 31, Issue 10, Pages 2037-2047
出版商
Springer Nature
发表日期
2017-01-11
DOI
10.1038/leu.2017.10
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
- (2016) Peter P. Ruvolo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
- (2016) Jungoh Ham et al. CANCER CELL
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
- (2016) Z Xu et al. LEUKEMIA
- Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia
- (2016) A Wallaert et al. LEUKEMIA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition
- (2015) Steven Tinsley et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract B30: Mechanisms of resistance to ABT-199 in leukemia and lymphoma cell lines
- (2015) Stephen K. Tahir et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia
- (2015) K Durinck et al. LEUKEMIA
- ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
- (2015) Nadine Johnson-Farley et al. LEUKEMIA & LYMPHOMA
- Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas
- (2015) Munevver Cinar et al. LEUKEMIA RESEARCH
- Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
- (2015) Ute Fischer et al. NATURE GENETICS
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
- (2015) D C Phillips et al. Blood Cancer Journal
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
- (2015) Gong-Quan Li et al. Oncotarget
- Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
- (2015) Gaurav S. Choudhary et al. Oncotarget
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
- (2015) David Chiron et al. Oncotarget
- Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
- (2015) Marie Loosveld et al. Oncotarget
- c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells
- (2014) J. E. Roderick et al. BLOOD
- ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
- (2014) S. Peirs et al. BLOOD
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
- (2014) Xiaoxian Zhao et al. BRITISH JOURNAL OF HAEMATOLOGY
- A revised definition for cure of childhood acute lymphoblastic leukemia
- (2014) C H Pui et al. LEUKEMIA
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
- (2014) S L Khaw et al. LEUKEMIA
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
- (2014) T. N. Chonghaile et al. Cancer Discovery
- BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction
- (2014) Amish J. Patel et al. Cell Reports
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Super-Enhancers in the Control of Cell Identity and Disease
- (2013) Denes Hnisz et al. CELL
- The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability
- (2013) Bryan King et al. CELL
- The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease
- (2013) E Mogilyansky et al. CELL DEATH AND DIFFERENTIATION
- Relapsed childhood acute lymphoblastic leukaemia
- (2013) Deepa Bhojwani et al. LANCET ONCOLOGY
- BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines
- (2013) N M Anderson et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
- (2012) D. Merino et al. BLOOD
- Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
- (2012) C.-H. Pui et al. BLOOD
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo
- (2011) Kristen L. Meerbrey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adult acute lymphoblastic leukemia
- (2010) Stefan Faderl et al. CANCER
- Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
- (2010) A. Oriol et al. HAEMATOLOGICA
- Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
- (2010) Laura Bonapace et al. JOURNAL OF CLINICAL INVESTIGATION
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now